Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methylphenidate hydrochloride extended-release chewable tablet
- Development stage
- Approved
- Lead developer
- Tris Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
QuilliChew ER is a central nervous system (CNS) stimulant formulated as an extended-release, cherry-flavored chewable tablet containing methylphenidate hydrochloride. It is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The drug works primarily by inhibiting the reuptake of dopamine and norepinephrine in the brain, thereby increasing their synaptic concentrations and enhancing neurotransmission in areas involved in attention and behavior regulation. Methylphenidate-containing medications are classified as Schedule II controlled substances due to their potential for abuse and dependence. QuilliChew ER was approved by the FDA in 2015 as a unique formulation designed for once-daily oral administration[1][2][3][4][5].
- Brand names
- QuilliChew ER
- Other names
- methylphenidate HCl extended-release chewable tabletmethylphenidate hydrochloride ER chewable tablet
02
Targets
NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on methylphenidate hydrochloride extended-release chewable tablet.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methylphenidate hydrochloride extended-release chewable tablet.